Physician profile
Stephen C Nelson
NPI 1104850569
$830.31
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $661 · 2020: $96.72 · 2021: $58.99 · 2022: $13.15.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $191.73 | 2019-2020 | |
| Janssen Biotech, INC. | $155.76 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $138.16 | 2019-2020 | |
| Abbvie INC. | $72.14 | 2021-2022 | |
| Viiv Healthcare Company | $70.81 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $54.52 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $36.40 | 2019 | |
| Gilead Sciences, INC. | $32.08 | 2019 | |
| Janssen Products, LP | $29.99 | 2019 | |
| Melinta Therapeutics, LLC | $29.65 | 2019 | |
| Astellas Pharma US INC | $19.07 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.